{"ok":true,"entity":{"id":"csl-limited","name":"CSL Limited","entityType":"company","officialName":"CSL Limited","canonicalName":"CSL Limited","displayName":"CSL Limited","category":"バイオ医薬品・血漿由来医薬品・ワクチン企業","shortDescription":"オーストラリア・メルボルンに所在するバイオ医薬品企業（ASX: CSL）。CSL Behring、CSL Plasma、CSL Seqirus、CSL Viforの事業を持つ。2026年8月18日発表の2026年6月期（FY26）決算で売上高158億米ドル、減損等により純損失26億米ドルを計上し、Gordon NaylorがInterim CEOを務める（2026年8月時点）。Seqirusの分離は2025年10月に延期が発表され、完了していない。","primaryCluster":"biotech-genomics","parentEntity":null,"verificationStatus":"draft","website":"https://www.csl.com","updatedAt":"2026-10-20T07:08:03.177Z","secondaryClusters":[],"alias":["CSL Ltd"],"searchKeywords":["CSL","CSL Limited","CSL Behring","CSL Seqirus","CSL Vifor","CSL Plasma","シーエスエル","血漿分画製剤","インフルエンザワクチン","メルボルン"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-05-001","P-06-001"]}